Caplin Point’s CRO division completes USFDA audit with nil observations

24 Sep 2021 Evaluate

Amaris Clinicals (Amaris), the Clinical Research Organization (CRO) division of Caplin Point Laboratories, located at Chennai, has completed a virtual audit from United States Food and Drug Administration (USFDA) with NIL observations.

The company targets approvals on mutual recognition basis from other regulatory bodies, including ones from Latin America, a key geography for Caplin Point.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1456.75 -0.85 (-0.06%)
12-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.75
Dr. Reddys Lab 6045.00
Cipla 1540.70
Zydus Lifesciences 1096.45
Lupin 1607.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.